NIKKEI 225
27,369.41 +6.66 (+0.02%) HANG SENG
22,559.20 -7.58 (-0.03%) CRUDE OIL
81.14 +0.13 (+0.16%) GOLD FUTURES
1,930.30 +0.30 (+0.02%) DOW
33,949.41 +205.57 (+0.61%) BTC-GBP
18,270.50 -506.49 (-2.70%)
Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 84.07 |
| Open | 83.76 |
| Bid | 83.07 x 800 |
| Ask | 83.43 x 800 |
| Day's range | 82.61 - 83.81 |
| 52-week range | 57.17 - 89.74 |
| Volume | |
| Avg. volume | 7,858,463 |
| Market cap | 104.88B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 31.67 |
| EPS (TTM) | 2.64 |
| Earnings date | 02 Feb 2023 |
| Forward dividend & yield | 2.92 (3.49%) |
| Ex-dividend date | 14 Dec 2022 |
| 1y target est | 86.33 |
- Zacks
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.
- Zacks
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Could Gilead Sciences Stock Help You Become a Millionaire?
Consider investing in stocks that have both attractive growth opportunities and that pay an above-average dividend. Before the end of last year, Gilead Sciences investors received some great news: The company's twice-yearly injectable treatment for HIV obtained approval from the Food and Drug Administration. With the approval, Gilead has added a potential blockbuster to its portfolio as analysts project Sunlenca could hit a peak of $1.5 billion in annual revenue.
